CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., today announced that the company and its collaborators will present a total of 29 studies, including two clinical science symposia presentations and two poster discussions, at the 2021 American Society of Clinical Oncology Virtual Scientific Program (ASCO21) from June 4-8. Among the presentations are data reinforcing the role of comprehensive genomic profiling (CGP) in increasing equitable patient access to precision medicine tools, as well as studies highlighting the clinical utility of CGP and the power of real-world data to inform treatment decisions and better understand disparities in care.

Highlights of these presentations include:

• new data emphasizing how the lack of early CGP testing and clinical trial enrollment in patients of African ancestry may help explain disparities in prostate cancer;
• clinical data reinforcing the value of tissue- and liquid-based CGP as tools for oncologists to identify predictive biomarkers and enable precision medicine; and
• additional evidence of the power of real-world data from Foundation Medicine and Flatiron Health’s joint clinico-genomic database (CGDB) to inform treatment decisions.

“At our core, Foundation Medicine is focused on using the highest quality insights to transform cancer care for everyone, and the breadth of data we’re presenting at ASCO in collaboration with our research and industry partners reflects that commitment,” said Brian Alexander, M.D., M.P.H., CEO at Foundation Medicine. “The data we’ll share with the oncology community will help us continue moving the needle on changing clinical care by showing the clinical value of CGP across the spectrum of cancers, as well as highlighting the need to consistently and equitably improve access to genomic testing so that every person facing a cancer diagnosis has the insights needed to inform the best possible care.”

Understanding Genomic Ancestry and CGP Utilization in Men with Prostate Cancer

In a study conducted in collaboration with Sylvester Comprehensive Cancer Center at the University of Miami, researchers investigated the genomic landscape and therapeutic implications of CGP in prostate cancer across men of European and African ancestry. Researchers believe this is the largest known cohort of its kind that describes CGP utilization, the genomic landscape from CGP, and treatment patterns in prostate cancer across ancestry groups. The analysis revealed men of African ancestry were less likely to receive CGP earlier in their treatment course and less likely to be treated in clinical trials. The findings potentially advance the field’s understanding of ancestry-based disparities in prostate cancer.

[Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis. Abstract #5003.]

Clinical Utility of Comprehensive Genomic Profiling

In a study exploring the genomic and immunologic profile of intrahepatic cholangiocarcinoma (IHCC) with IDH1/2 genetic alterations in partnership with The University of Texas MD Anderson Cancer Center and others, researchers found significant differences in alterations between IDH1+/IDH2+ IHCC and IDH wild-type IHCC. The data suggest these alterations are IHCC driver oncogenes and support investigation of IDH inhibitors in these patients.

[IDH1 and IDH2 driven intrahepatic cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study. Abstract #4009]

In a real-world clinical outcomes study of alpelisib in patients with PIK3CA-mutated breast cancer conducted in partnership with UCSF Helen Diller Family Comprehensive Cancer Center, researchers validated the effectiveness of alpelisib in a diverse, real-world population. Results showed these patients had longer progression-free survival with alpelisib plus fulvestrant than with fulvestrant alone. The study also showed liquid biopsy CGP detected PIK3CA mutations at a similar rate to tissue biopsy, reinforcing the clinical utility of both testing types depending on the patient’s unique situation.

[Real world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm). Abstract #1068]

As the cancer community works to expand access to precision medicine trials to more patients, the need for decentralized trials has become increasingly apparent. In the Alpha-T study, a clinical trial sponsored by Roche using Foundation Medicine’s precision enrollment services, researchers at multiple institutions, including UCSD Moores Cancer Center and Vanderbilt University Medical Center, are investigating patients with ALK-positive solid tumors, identified through either liquid or tissue biopsy, being treated with alectinib. Through remote support, patients are participating in the trial from their local care setting, demonstrating the potential of decentralized trials to increase broader and more diverse enrollment in clinical trials.

[Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting. Abstract #TPS3155]

Power of Real-World Data to Advance Personalized Medicine

Using the CGDB, researchers assessed outcomes for metastatic breast cancer patients with somatic BRCA or other homologous recombination (HR)-pathway mutations treated with a PARP inhibitor. Results suggested these patients had similar benefit from PARP inhibitor treatment compared to patients with germline BRCA mutations, supporting future studies of this targeted treatment approach for these patients.

[Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi). Abstract #10512]

Leveraging routine CGP testing of metastatic castrate resistant prostate (mCRPC) cancer tissue samples, researchers discovered that patients with biomarkers routinely assessed by CGP, including AR amplification, may help predict which patients are likely to benefit from taxane chemotherapy instead of novel hormonal therapy.

[Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC). Abstract #5054]

The following is a list of select abstracts that will be presented at the meeting. To access all abstracts being presented by Foundation Medicine and its collaborators, please visit: meetinglibrary.asco.org.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter.

Foundation Medicine^® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005259/en/